In vitro permeability study of nasal medicinal product for systemic action

封面

如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

For systemic medicinal products bioavailability is a fundamental characteristic that determines their efficacy and onset of action. Biopharmaceutical parameters of nasal preparations (physicochemical properties of the active substance such as membrane permeability, solubility, lipophilicity, pKa, polymorphic state, type of finished dosage form, pH, osmolarity, composition and characteristics of excipients), affecting bioavailability, are variable and controllable within pharmaceutical development. Besides the use of components that affect enzymatic activity, mucoadhesion and effective contact time, mucociliary clearance and viscosity of mucous secretion, changing the rate and degree of absorption of the active substance is possible by modulation of tight junctions and paracellular transport. These processes can be particularly determined by the osmolarity of the dosage form and the use of permeation enhancers. Taking into account the portfolio of excipients available to scientists used in a wide range of concentrations, and, in addition, the requirements of the target product profile in terms of safety and pharmacokinetic parameters, as well as regulatory recommendations for justification of the composition within pharmaceutical development, with particular emphasis on the selection of functional components and the concentrations used, it is important to have relevant and reliable screening tools when formulating a drug product. Due to the absence of standard bioavailability assessment methods for nasal preparations, literature review was conducted and methodology of in vitro permeability study for of nasal medicinal products for systemic action with the use of artificial membranes as well as cell line RPMI 2650 of human nasal epithelium is developed. The use of such sufficiently homogeneous barrier films allows to minimize the variability of test conditions. Permeation study of developed compositions of antimigraine medicinal product is conducted. The results obtained provide evidence of their qualitative compliance and allow to recommend laboratory permeability study on cellulose membranes for the selection and justification of the composition of pharmaceutical compositions.

Bioavailability is a fundamental characteristic of pharmaceutical products for systemic action, which defines efficacy and speed of action. Permeability through biological membranes is defined not only by the properties of active component but also by the particulars of formulation. Due to the absence of standard bioavailability assessment methods for nasal preparations, literature review was conducted and methodology of in vitro permeability study for of nasal medicinal products for systemic action with the use of artificial membranes as well as cell line RPMI 2650 is developed. Permeation study of developed compositions of antimigraine medicinal product is conducted. The results obtained provide evidence of their qualitative compliance and allow to recommend laboratory permeability study on cellulose membranes as a screening tool in pharmaceutical development.

全文:

受限制的访问

作者简介

I. Vlasenko

Ferring Production LLC

编辑信件的主要联系方式.
Email: julietvlasenko@gmail.com
ORCID iD: 0000-0003-3830-8310

General Director

俄罗斯联邦, Moscow

参考

  1. EMA/CHMP/QWP/911254/2011 Guideline on quality of transdermal patches. Режим доступа: https://www.ema.eu-ropa.eu/en/documents/scientific-guideline/draft-guideline-quality-transdermal-patches_en.pdf (дата обращения / accessed: 05.04.2024)
  2. Inoue D., Furubayashi T., Tanaka A. et. al. Quantitative estimation of drug permeation through nasal mucosa using in vitro membrane permeability across Calu-3 cell layers for predicting in vivo bioavailability after intranasal administration to rats. European Journal of Pharmaceutics and Biopharmaceutics. 2020;149:145–153. doi: 10.1016/j.ejpb.2020.02.004.
  3. Bartos C., Szabó-Révész P., Horváth T. et. al. Comparison of Modern in vitro Permeability Methods with the Aim of Investigation Nasal Dosage Forms. Pharmaceutics. 2021;13(6):846. doi: 10.3390/pharmaceutics13060846.
  4. Zhang H., Lin C.W., Donovan M.D. Correlation between Nasal Membrane Permeability and Nasal Absorption Rate. AAPS PharmSciTech. 2013;14(1):60–63. doi: 10.1208/s12249-012-9884-2.
  5. Belgamwar S.V., Patel H.S., Joshi A.S. et. al. Design and development of nasal mucoadhesive microspheres containing tramadol HCl for CNS targeting. Drug Delivery. 2011;18(5):353–360. doi: 10.3109/10717544.2011.557787.
  6. Bhanushali R.S., Bajaj A.N. Design and development of thermoreversible mucoadhesive microemulsion for intranasal delivery of sumatriptan succinate. Indian J Pharm Sci. 2007;69(5):709–712. doi: 10.4103/0250-474X.38487.
  7. Bartos C., Ambrus R., Kovács A. et. al. Investigation of Absorption Routes of Meloxicam and Its Salt Form from Intranasal Delivery Systems. Molecules. 2018;23(4):784. doi: 10.3390/molecules23040784.
  8. Naik A., Nair H. Formulation and Evaluation of Thermosensitive Biogels for Nose to Brain Delivery of Doxepin. Biomed Res Int. 2014:847547. doi: 10.1155/2014/847547.
  9. Shah S.S., Gohil D.Y., Pandya D.N., Meshram D.B. Preparation and evaluation of spray-dried mucoadhesive microspheres for intranasal delivery of prochlorperazine using factorial design. Asian Journal of Pharmaceutics. 2015;9(3):178–189. doi: 10.4103/0973-8398.160314.
  10. Tas C., Ozkan C.K., Savaser A. et. al. Nasal administration of metoclopramide from different dosage forms: in vitro, ex vivo, and in vivo evaluation. Drug delivery. 2009;16(3):167–175. doi: 10.1080/10717540902764172.
  11. Basu S., Bandyopadhyay A.K. Development and Characterization of Mucoadhesive in situ Nasal Gel of Midazolam Prepared with Ficus carica Mucilage. AAPS PharmSciTech. 2010;11(3):1223–1231. doi: 10.1208/s12249-010-9477-x.
  12. Hasçiçek C., Gönül N., Erk N. Mucoadhesive microspheres containing gentamicin sulfate for nasal administration: preparation and in vitro characterization. Farmaco. 2003;58(1):11–16. doi: 10.1016/S0014-827X(02)00004-6.
  13. Henriques P., Bicker J., Carona A. et. al. Amorphous nasal powder advanced performance: in vitro/ex vivo studies and correlation with in vivo pharmacokinetics. J. Pharm. Investig. 2023;53(5):723–742. doi: 10.1007/s40005-023-00630-1.
  14. Werner U., Kissel T. Development of a Human Nasal Epithelial Cell Culture Model and Its Suitability for Transport and Metabolism Studies Under in Vitro Conditions. Pharm. Res. 1995;12(4):565571. doi: 10.1023/A:1016210231121.
  15. Werner U., Kissel T. In vitro Cell Culture Models of the Nasal Epithelium: A Comparative Histochemical Investigation of Their Suitability for Drug Transport Studies. Pharm. Res. 1996;13(7):978–988. doi: 10.1023/A:1016038119909.
  16. Schmidt M.C., Peter H., Lang S.R. et. al. In vitro cell models to study nasal mucosal permeability and metabolism. Adv Drug Del Rev. 1998;29(1-2):51–79. doi: 10.1016/S0169-409X(97)00061-6.
  17. Sarmento B., Andrade F., Baptista da Silva S. et. al. Cell-based in vitro models for predicting drug Permeability. Expert Opin Drug Metab Toxicol. 2012;8(5):607–621. doi: 10.1517/17425255.2012.673586.
  18. Srinivasan B., Kolli A.R., Esch M.B. et. al. TEER Measurement Techniques for in vitro Barrier Model Systems. J Lab Autom. 2015;20(2):107–126. doi: 10.1177/2211068214561025.
  19. Gonçalves V.S.S., Matias A.A., Poejo J. et. al. Application of RPMI 2650 as a cell model to evaluate solid formulations for intranasal delivery of drugs. International Journal of Pharmaceutics. 2016;515(1):1–10. DOI: 0.1016/j.ijpharm.2016.09.086.

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1. Change in TEER value during the experiment (dashed lines) and cumulative permeability profile (solid lines) for the test samples, expressed as a percentage of the corresponding initial values

下载 (149KB)
3. Fig. 2. Mass of active substance on the basolateral side during the experiment for each test sample

下载 (105KB)

版权所有 © Russkiy Vrach Publishing House, 2024
##common.cookie##